Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
Novel dementia targets and target validation work conducted by academics will be partnered with the drug discovery expertise of the Dementia Consortium. We provide full funding for projects along with access to expert in vitro biology knowledge, high-throughput screening, chemical and fragment libraries, medicinal chemistry and antibody engineering teams. Grant holders have regular project review meetings with members of the Dementia Consortium to help progress successful projects from early research findings through to target validation and drug discovery. Promising targets are moved towards the clinic through the successful licence of these projects to industrial partners with the ultimate aim of bringing benefit to patients.
Característiques principals
Scope of projects:
  • Projects focused on novel molecular targets in neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, tauopathies, vascular dementia, amyotrophic lateral sclerosis, frontotemporal dementia, Huntingdon’s disease.
  • Evidence linking the target to human disease and a strong rationale for target modulation having a therapeutic effect.
  • Collaborators with strong biology expertise and access to enabling assays, reagents and disease models. The following projects are not in scope for funding:
  • Projects focused on well-studied targets and pathways for neurodegenerative diseases.
  • Projects with advanced chemistry e.g. lead/candidate molecules already synthesised and requiring only in vivo PK studies, preclinical proof-of-concept studies or IND-enabling studies.
  • Repurposing of existing drugs, although we will consider optimisation of tool / literature compounds to improve selectivity, potency, bioavailability, etc.
  • Non-pharmacological interventions e.g. behavioural changes.

    Previous experience in drug discovery is not required, nor do you need to have any in-house capability for carrying out drug development. The Consortium is able to provide all of the assay development, screening and medicinal chemistry resources required to develop novel compounds or antibodies against the target.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
    • Carol Barnwell, cbarnwell@imim.es. Ext.: 1670
    • Marta López, mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    http://www.dementiaconsortium.org/
    Impresos (URL)
    Please register to receive the Dementia Consoritum expression of interest:
    https://a-r.org.uk/Login.aspx?ReturnUrl=%2f
    Requisits
  • Lead applicant should have contract which will cover their salary for at least the duration of the grant
  • Principal Investigators as co-applicants should have a tenured position
    • Dotació
    Typical costs £100-250k. Notional limit £500k, for exceptional cases
    Durada
    Typically 2-3 years.
    AVÍS IMPORTANT
    Open, ongoing application process. Closing dates are roughly every three months.
    For additional information on the application process, please see the Launch Event Slides.

    Arxius

    Arxiu
    Dementia-Consortium-Launch-Event-Final-ppt (4) (1).pdf